Cord serum 25-hydroxyvitamin D and risk of early childhood transient wheezing and atopic dermatitis
Nour Baïz, Patricia Dargent-Molina, John Wark, Jean-Claude Souberbielle, Isabella Annesi-Maesano

To cite this version:

HAL Id: inserm-01124405
http://www.hal.inserm.fr/inserm-01124405
Submitted on 6 Mar 2015

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Cord serum 25-hydroxyvitamin D and risk of early childhood transient wheezing and atopic dermatitis

Nour Baïz, PhD\textsuperscript{a,b}, Patricia Dargent-Molina, PhD\textsuperscript{c,d}, John D Wark, PhD\textsuperscript{e}, Jean-Claude Souberbielle, PhD\textsuperscript{f}, Isabella Annesi-Maesano, MD, DSc, PhD\textsuperscript{a,b}, and the EDEN Mother-Child Cohort Study Group

\textsuperscript{a} Inserm (Institut national de la santé et de la recherche médicale), Epidemiology of Allergic and Respiratory diseases (EPAR) Department, UMR-S707, Paris, France; \textsuperscript{b} Medical School Saint-Antoine, UPMC Univ6, Paris, France; \textsuperscript{c} Inserm, Epidemiological Research in Perinatal Health and Women’s and Child Health, UMR-S953, Villejuif, France; \textsuperscript{d} University Pierre and Marie Curie, UMR-S953, Paris, France; \textsuperscript{e} Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Vic., Australia; \textsuperscript{f} Laboratoire de physiologie, université Paris-Descartes, hôpital Necker–Enfants-Malades, Assistance Publique–Hôpitaux de Paris, Paris, France.

Corresponding author: Nour Baïz, EPAR UMR-S 707 INSERM & UPMC Paris 6, Medical School Saint-Antoine, 27 rue Chaligny 75571 Paris CEDEX 12, France. Tel: +33 (0)1 44 73 86 58. Fax: +33 (0)1 44 73 84 54, E-mail: baiz@u707.jussieu.fr
Abstract

Background: There is increasing evidence of the effect of maternal vitamin D intake during pregnancy on the risk of asthma and allergic outcomes in the offspring. However, studies on the relationship between cord levels of 25-hydroxyvitamin D (25[OH]D) and asthma and allergic diseases are very few.

Objective: Our aim was to investigate the associations between cord serum 25(OH)D levels and asthma, wheezing, allergic rhinitis and atopic dermatitis in the offspring from birth to 5 years.

Methods: Cord blood samples were collected at birth and were analyzed for levels of 25(OH)D in 239 newborns from the EDEN birth cohort. The children were followed up until age 5 years by symptom ISAAC-based questionnaires (International Study of Asthma and Allergies in Childhood).

Results: The median cord serum level of 25(OH)D was 17.8 ng/mL (interquartile range: 15.1 ng/mL). Using multivariable-adjusted logistic regression models, a significant inverse association was observed between cord serum 25(OH)D and risk of transient early wheezing and early and late-onset atopic dermatitis, as well as atopic dermatitis by the age of 1, 2, 3 and 5. We found no association between cord serum 25(OH)D levels and asthma and allergic rhinitis at 5 years of age.

Conclusions: Cord serum 25(OH)D level was inversely associated with the risk of transient early wheezing and atopic dermatitis by the age of 5 years, but no association was found with asthma and allergic rhinitis.
Clinical implications: The risk of transient wheezing and atopic dermatitis in childhood is inversely associated with cord 25(OH)D levels. Interventions to increase vitamin D levels *in utero* and in early life are potential public health interventions to reduce transient wheezing and atopic dermatitis in young children.

Capsule summary: Although research is required to establish the optimal level, timing and route of exposure, recommendations for adequate vitamin D intake in pregnant women may prevent transient early childhood wheezing and atopic dermatitis.

Keywords: Vitamin D; 25-hydroxyvitamin D; Cord blood; Allergic diseases; Wheezing; Atopic dermatitis; Mother-child cohort

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; EDEN, Etude des Déterminants pré et post natals du développement et de la santé de l'Enfant; ISAAC, International Study of Asthma and Allergies in Childhood; OR, odds ratio; CI, confidence interval; SD, standard deviation.
Introduction

Over the last decade, the prevalence of allergies and asthma in childhood has increased worldwide, particularly in westernized societies. There is increasing evidence that fetal life and early life exposures, along with associated epigenetic changes (1), are important determinants of the future development of asthma and allergies throughout life (2). Among other environmental factors, prenatal and early life dietary exposures, including vitamin D, have been suggested to play an important role in the development of allergies and asthma in childhood (3).

Vitamin D deficiency, defined as a circulating level of < 20 ng/mL of 25-hydroxyvitamin D (25(OH)D), has become a public health issue (4). It has been largely attributed to dietary, lifestyle and behavioral changes during recent decades (4), especially in Western countries. Children as well as pregnant and lactating women are identified as groups vulnerable to vitamin D deficiency (5).

While the relationship of vitamin D deficiency and rickets is well established (6), and its association with a wide variety of medical conditions including microbial infections (7), cardiovascular diseases (8), cancers (9), autoimmune diseases (10) and diabetes (11) is well documented, only more recently has the role of vitamin D deficiency and insufficiency in asthma (12-14) and allergic diseases (15) beginning in infancy or childhood (16-18) been debated. In the last couple of decades in the twentieth century and early in the twenty-first century, the vitamin D receptor has been found in a variety of cells, including keratinocytes and numerous cells of the immune system (e.g., dendritic cells, natural killer cells) (19).

Several lines of evidence demonstrate the effects of vitamin D on pro-inflammatory cytokines, regulatory T cells, and immune responses (20).

Vitamin D is found naturally in very few dietary sources, the only really significant being fatty fish (21) and vitamin D-fortified foods. The latter are scarce in France. The main
source of vitamin D in humans is synthesis from 7-dehydrocholesterol in the skin upon
exposure to ultraviolet B solar radiation and conversion to a readily-measurable circulating
metabolite, 25-hydroxyvitamin D (25(OH)D) in the liver (21). Circulating 25(OH)D is the
best index of vitamin D nutritional status (21). Low intake of vitamin D and inadequate
exposure to sunlight constitute the main causes of vitamin D deficiency. A number of factors
may influence the cutaneous synthesis and dietary sources of vitamin D (22), especially in
pregnant women (23). These factors include season of the newborn’s birth, maternal vitamin
D intake, body mass index, constitutive skin pigmentation, latitude, clothing, sunscreen-use,
outdoors activities, age (22,23) and genetic factors (24).

During pregnancy the fetus is exposed to vitamin D through cord blood supply and the
ability of 25(OH)D to cross the placenta (25). Over the past 2 years, the number of studies,
both cross-sectional and prospective, that have investigated the effects of maternal vitamin
D intake on the inception and severity of asthma and allergies in the offspring have increased
significantly. Most studies have shown that low maternal vitamin D levels (assessed by food
frequency questionnaires) increase the risk for asthma (26), wheeze (18,27,28) allergic
rhinitis (26) and atopic dermatitis (18), but a few suggest an increased risk with high levels
(29-30).

However, the majority of these studies did not use objective measures of maternal
vitamin D status. In addition, studies examining the associations between cord blood
25(OH)D concentrations and asthma and allergic diseases (16) are still very scarce.

The purpose of the present study was to investigate whether the levels of cord serum
25(OH)D, which is considered the best indicator of newborns’ vitamin D status, are
associated with risk of asthma, wheeze, allergic rhinitis and atopic dermatitis in offspring. Our
study was conducted in the French EDEN mother-child cohort.
Methods

Study design and participants

Mother-child pairs were recruited in the EDEN (Etude des Déterminants pré et post natals du développement et de la santé de l'Enfant) prospective Birth Cohort Study (http://eden.vjf.inserm.fr). The primary aim of the EDEN Cohort is to identify prenatal and early postnatal nutritional, environmental and social determinants associated with children’s health and their normal and pathological development. Pregnant women seen for a prenatal visit at the departments of Obstetrics and Gynecology of the University Hospital of Nancy and Poitiers before their twenty-fourth week of amenorrhea were invited to participate. Enrolment started in February 2003 in Poitiers and September 2003 in Nancy; it lasted 27 months in each centre. Women with speaking and writing abilities in French, who did not suffer from type 2 diabetes diagnosed prior to pregnancy, and did not plan to deliver outside the university hospital or move out of the region within 3 years, were included in the study. Multiple pregnancies were excluded. Among eligible women, 55% (2002 women) agreed to participate (1034 women in Nancy and 968 in Poitiers). Of the 2002 mother-child pairs included in the EDEN study, 1140 of them had complete data by the child’s age of 5 years. Among the 1140 participants, measurements of cord serum 25(OH)D performed at birth were available in 239 children. The final sample for analysis consisted of 239 mother-child pairs. This sample appeared representative of the overall study population.

Women were given an appointment with a study midwife, planned to take place between 24 and 28 gestational weeks, during which an interview on behavioral factors was conducted and biological samples were collected. Further information on the mothers and their newborns, including parity, mode of delivery, newborn’s sex and birth weight (measured with electronic Seca scales, Hamburg, Germany [Seca 737 in Nancy and Seca 335 in Poitiers...
with a 10 g precision], gestational age and season of birth, were either collected by a
questionnaire after birth or extracted from obstetrical and pediatric records. All children were
equally receiving vitamin D supplementation during the first three years of life.

Ethics Statement

The ethical committees who approved the study is: Comité Consultatif pour la
Protection des Personnes dans la Recherche Biomédicale, Le Kremlin-Bicêtre University
hospital, and Commission Nationale de l’Informatique et des Libertés. The study was
approved on 12 December 2002. Written consent was obtained from the mother for herself at
the beginning of the study and from both parents for the newborn child after delivery.

Cord serum 25(OH)D measurement

Immediately after delivery, cord blood serum samples were collected by research
midwives. In order to prevent any contamination with maternal blood, the cord was doubly
clamped immediately after birth (vaginal delivery) or after extraction of the fetus through the
uterine incision (elective caesarean section); repeatedly rinsed and venous cord blood serum
was sampled between the two clamps. Blood samples were centrifuged within 24 hours of
collection. The serum was separated and stored at −80°C. Standard operating procedures for
each assay were established. Serum 25(OH)D, which is considered to be the indicator of
vitamin D status (31), was measured by immunochemilumiscent immunoassays performed on
the LIAISON platform manufactured by DiaSorin (Sallugia, Italy). This assay measures both
25(OH)D2 and 25(OH)D3 and provides the sum of these two metabolites and does not cross-
react with the C3 25(OH)D epimer, which has been shown to complicate the measurement of
25(OH)D in neonates. The intra- and interassay coefficient of variation was <10% whatever
the measured concentration.
Health outcomes

Children were followed up from birth to age 5 years. At the age of 1, 2, 3 and 5 years, parents completed questionnaires including questions on asthma, wheeze, allergic rhinitis and atopic dermatitis, based on the validated International Study of Asthma and Allergies in Childhood (ISAAC) phase-I questionnaire (32,33). For each year, asthma was defined as parental report of doctor-diagnosis of asthma plus either one or more attacks of wheeze or asthma medication in the last 12 months. Wheeze was defined as present if the parents answered ‘‘yes’’ to the question ‘‘Has your child had wheezing or whistling in the chest in the preceding 12 months?’’. Parental report of wheezing has been shown to be a sensitive and specific outcome when using physician assessment as the criterion standard (34). Allergic rhinitis was defined as sneezing, nasal congestion, or rhinitis, other than with respiratory infections, accompanied by eye itching and tearing during the previous 12 months (35). And atopic dermatitis was defined as atopic dermatitis diagnosed by a doctor in the last 12 months.

Given the uncertainty of allergic rhinitis and asthma diagnoses in early childhood (36), analyses were performed on allergic rhinitis and asthma from age 4 to 5 (positive answers to the previous questions in the 5 year-questionnaire). Lifetime prevalence of wheeze and atopic dermatitis at 1, 2, 3 and 5 years were analyzed.

Additionally, the data on wheezing from 1 to 5 years of age were used to categorize the children as never wheezers, early transient wheezers, late-onset wheezers, or persistent wheezers according to Martinez et al. (37). Similarly, we distinguished between early- and late-onset atopic dermatitis, e.g. atopic dermatitis up to age 2 years and thereafter.

Other Variables
We collected information on potential confounders related to offspring health outcomes, including newborn sex, birth weight, gestational age, season at birth, number of older siblings at birth (0, 1 – 2, ≥ 3), exclusive breastfeeding for ≥ 4 months (yes or no), maternal age at delivery (< 25 years, 25–34 years, or > 34 years), pre-pregnancy maternal body mass index (18.5 – 24.9, 25.0 – 29.9, 30.0 – 34.9 and 35.0 – 39.9 kg/m²), maternal and paternal history of allergies (yes or no), maternal and paternal education level (primary or less, secondary, and university degree or higher), household income (≤ 2300 versus > 2300 Euros per month, median income of the study population), city of residence (Nancy or Poitiers), any smoking during pregnancy (yes or no), environmental tobacco smoke exposure of the child from birth to age of 3 (yes or no), dampness in housing (0 – 3 years) (yes or no), and day care attendance in the first year of life (yes or no). Maternal and paternal allergic history was obtained regarding physician-diagnosed allergic diseases such asthma, rhinitis, eczema and food allergies.

Statistical analyses

The sample was described using frequencies of categorical variables and means and standard deviations of continuous variables. The characteristics of the mother-newborn pairs in our study sample (n = 239) were compared to the sample of mother-newborn pairs of children without measurement of cord serum 25(OH)D (n = 901). We used Chi-square tests for categorical data, T-tests for normally-distributed data and Mann-Whitney U tests for skewed data.

We fitted logistic regression models to examine the associations between cord serum 25(OH)D level as a continuous variable and asthma and allergic rhinitis reported from 4 to 5 years and wheeze and atopic dermatitis by the age of 1, 2, 3 and 5 years, as well as the wheezing and atopic dermatitis patterns.
In order to identify confounding factors, bivariate analysis between potential confounders and each health outcome were performed. In a first step, all variables associated with one health outcome with a p<0.30 were retained. In a second step, confounders affecting at least 20% of the coefficient estimates of the investigated association between vitamin D and the health outcome were selected and included in the multivariate models. In addition to the inclusion of confounders based on their statistically significant association with health outcomes, we selected other adjustment variables, on the basis of their known relationship to 25(OH)D concentrations, independently of any association with exposures and regardless of whether they changed the effect estimates significantly. They included: child’s sex (38), pre-pregnancy body mass index (39), and birthweight (40). As a result, the adjustments included: city, maternal age at delivery, maternal pre-pregnancy body mass index (BMI), any smoking during pregnancy, any passive smoke exposure during the first 3 years of life, number of siblings, household income, newborn’s sex and weight, season of birth (calendar-based), and exclusive breastfeeding for ≥ 4 months. Multiple logistic regression analysis was used to adjust for confounding factors. Estimations of crude and adjusted odds ratios (ORs) and their 95% confidence interval (CI) of asthma, wheeze, allergic rhinitis and atopic dermatitis, at different time point, per 5 ng/mL increase of cord serum 25(OH)D concentration were made by means of logistic regression analysis.

To further explore the associations between asthma and allergic rhinitis and cord vitamin D, we examined effect modification of the association of these outcomes with cord serum 25(OH)D, by stratifying the cohort according to maternal history of allergy and testing the interaction term (namely continuous 25(OH)D*maternal history of allergy). All statistical analyses were performed using SAS statistical software version 9.2 (SAS Institute Inc, Cary, North Carolina). P-values < 0.05 were considered statistically significant for all analyses.
Results

Characteristics of the mother-child pairs

Children with both cord serum 25(OH)D data and complete questionnaires from birth to 5 years of age were included in this analysis (n = 239). Included children did not differ significantly from other children with complete questionnaires up to 5 years of age but without measurement of cord serum 25(OH)D (n = 901) with respect to all characteristics, except for season of birth and city of residence (Table I).

In our study population, no mothers reported type 2 diabetes diagnosed prior to pregnancy or chronic illnesses apart from asthma, eczema and other allergic diseases, such as rhinitis and food allergies.

Health outcomes in the offspring

By the age of 1, 2, 3 and 5 years, 24.7%, 32.6%, 35.1% and 38.9% of all children had experienced wheezing, respectively, and 10%, 13.4%, 14.2% and 25% had had atopic dermatitis, respectively. From age 4 to 5, 8% of all children had asthma and 7.5% had allergic rhinitis. The prevalences of early transient, late-onset and persistent wheezing patterns were 28.5%, 11.7% and 4.2%, respectively. The prevalences of early-onset and late-onset atopic dermatitis were 34.7% and 20.5%, respectively.

Newborns’ cord serum levels of 25(OH)D

Figure 1 shows the distribution of cord blood serum 25(OH)D concentrations. The mean concentration and the interquartile range (IQR) in cord blood serum were 17.8 ng/mL and 15.1 ng/mL.

Relationship of cord serum 25(OH)D and outcomes by the age of 5 years
The associations between cord serum 25(OH)D levels and risk of different wheezing patterns, atopic dermatitis by the age of 1, 3 and 5 years, different atopic dermatitis patterns, and asthma and allergic rhinitis at 5 years of age are presented in table II. Without adjustment, a significant inverse association was observed between cord serum 25(OH)D concentration (per 5 ng/mL increase) and the risk of early transient wheezing and atopic dermatitis by the age of 3 and 5 years and early and late-onset of atopic dermatitis. After multivariable adjustment, the previously observed significant inverse associations persisted (OR for early transient wheezing, per 5 ng/mL increase of cord serum 25(OH)D concentration: 0.67 (0.54–0.81); OR for atopic dermatitis by the age of 1, 3 and 5 years: 0.84 (0.71–1.00), 0.82 (0.68–0.97), 0.75 (0.63–0.88), respectively; and OR for early and late-onset atopic dermatitis: 0.73 (0.62–0.90), 0.75 (0.60–0.94), respectively). The adjusted inverse association along with the confidence intervals and the regression line, between cord serum 25(OH)D concentration and risk of atopic dermatitis by the age of 5 years is shown in Figure 2. The graph represents the predicted probability of atopic dermatitis by the age of 5 years for each observed value of cord serum 25(OH)D concentration in the multivariate model.

In contrast, no significant association was observed between cord serum 25(OH)D level and asthma and allergic rhinitis prevalence. To further investigate this null finding, we stratified each of these outcomes according to maternal history of allergy. In all models, cord serum 25(OH)D levels had no association according to either atopic or non-atopic maternal status (all $P > 0.20$).

**Discussion**

**Main findings**

In this prospective birth cohort study of French mother-child pairs, we found that cord serum concentration of 25(OH)D was negatively associated with early transient wheezing,
atopic dermatitis by the age of 1, 3 and 5 and early and late-onset atopic dermatitis. However, cord serum 25(OH)D levels were not associated with risk of other wheezing phenotypes, asthma and allergic rhinitis at 5 years of age.

In literature

To date, there is sparse information on vitamin D status and wheezing and atopic dermatitis. The few studies that have investigated the association between maternal vitamin D status and risk of wheezing (41) and atopic dermatitis (18) in childhood are limited by the fact that vitamin D intake was based only on food frequency questionnaires (18,28). Although such methods have been validated and are representative of intake over a period of time, most of these observational studies did not have direct serological measures of 25(OH)D levels to accurately confirm vitamin D status. However, all studies adjusted for total energy intake and for other nutrients associated with healthy diets.

Additionally, a study in 2008 found that vitamin D supplementation significantly improved skin symptoms in children with winter-related atopic dermatitis (42). And in adults, Oren et al. (43) also found a protective effect of vitamin D on atopic dermatitis. These results raise interesting questions about the potential role of vitamin D in the pathogenesis of atopic dermatitis.

Regarding the relationship between early transient wheezing and vitamin D deficit, Martinez et al. (37) found evidence that, in most cases, infant wheeze is a transient condition, not associated with increased risk of asthma or allergies later in life. In transient wheezer infants, a reduced airway caliber seems to be the predisposing factor to wheeze in association with viral infections. In our study, the inverse association between cord serum 25(OH)D
levels and early transient wheezing is consistent with Camargo et al. findings (16) of an inverse relationship between cord blood 25(OH)D levels and respiratory infections.

Potential mechanisms

Cord vitamin D may play a protective role against transient wheezing through its effects on the immune function (44,45). The molecular effects of vitamin D in the skin have been well documented in experimental studies. Vitamin D receptor (VDR) expression in the skin was first confirmed after rats injected with radio-labeled 1,25-dihydroxyvitamin D (1,25(OH)2D), the active form of 25(OH)D, demonstrated radioactivity concentrated in the nuclei of the epidermis along with a variety of other tissues (46). 1,25(OH) enhances keratinocyte differentiation, as well as have either stimulatory or suppressive effects on keratinocyte growth that is concentration dependent (47).

In addition, there is evidence to suggest that vitamin D decreases inflammatory responses in epidermal keratinocytes (48-50). In vitro treatment of dendritic cells (DCs) with 1,25(OH)2D or vitamin D analogues led to decreased IL-12 and enhanced IL-10. These cytokine effects, along with inhibitory effects on DC maturation, promote tolerogenic properties and suppressor T cell induction (51). A short treatment course of 1,25(OH)2D in mice induced tolerogenic DCs and increased regulatory T cells (52). As a result, vitamin D may promote regulatory T cells that are known to play an important role in the prevention of atopic dermatitis development (53) by playing a pivotal role in immune suppression and being crucial to the control of allergic responses.

Vitamin D also has a beneficial effect on the permeability barrier in the epidermis. Bikle et al. examined mice null for the expression of 25(OH)D-1α-hydroxylase. Lower levels of multiple proteins necessary for formation of the stratum corneum, including filaggrin, were observed in the null mice compared to the wild type controls (54). Following skin barrier
disruption, null mice had a significantly delayed barrier recovery compared to wild type mice (54).

Another potential role for vitamin D is suggested by the work of Schauber et al. (55), who found that 1,25(OH)2D enables keratinocytes to recognize and respond to microbes through action on the Toll-like receptor 2 and leads to upregulation of cathelicidin, an antimicrobial peptide. As a result, vitamin D may promote the production of antimicrobial peptides that have the ability to enhance immunity and protect skin from bacterial infections.

Consequently, given the fact that the pathogenesis of atopic dermatitis involves both epidermal barrier and immunologic dysfunction, vitamin D may have a protective role against atopic dermatitis and the development of a variety of other skin disorders as well.

Strengths and limitations

First, this is one of the few birth cohort studies to have measured vitamin D levels in cord blood as opposed to estimating infant levels based on vitamin D levels in pregnant women (30) or maternal intake of vitamin D during pregnancy (18,26,28,41). Additionally, newborns’s vitamin D status was assessed by measuring serum levels of 25-hydroxyvitamin D, which is considered the best circulating biomarker of vitamin D metabolic status. The analyses were performed on the continuous 25(OH)D variable, since the often used categorization of vitamin D levels is still arbitrary and without consensus. An additional strength of our prospective investigation consists in the robustness of the results as children were drawn from a cohort and their parents were able to provide information on possible confounders, thus diminishing the probability of biased or confounded results. In addition, we collected outcome data at different ages, providing more robust measures of potential health effects than single time-point outcomes could provide. The definition of health outcomes was based on the validated ISAAC questions.
Our study also has some limitations. Information on offspring health outcomes was obtained from parental report through self-administered questionnaires, which could result in misclassification. We could not obtain vitamin D data from all eligible newborns with complete information at age 5 years, which may have introduced selection bias. Because of the sample size of our study, although the change-in-estimate (CE) criterion ≥ 10% is a conventional one (56), a more conservative criterion ≥ 20% was used in order to select potential confounders. In addition, the absence of significant associations between asthma, allergic rhinitis and 25(OH)D concentrations may be due to the low prevalences of these outcomes, consequently limiting the power to detect a relationship between 25(OH)D and the outcome. An often-cited limitation of serologic studies is the reliance on a single 25(OH)D measurement per subject. It would have been interesting to measure serum 25(OH)D levels during childhood. The half-life of serum 25(OH)D is approximately 2 to 3 weeks (57), which suggests that the measured concentrations reflect maternal-fetal status during the final months of pregnancy and first months of life. All children in our study were receiving vitamin D supplement during the first three years of life, so difference between children vitamin D levels may depend on diet along with food diversification and on sun-related behaviors, despite heightened awareness of the carcinogenic effect of sun exposure (58). Finally, subjects were followed only to age 5 years, at which age asthma may be evolving from being infection-related to being predominantly related to allergy. Similarly, wheezing in the preschool years is not necessarily indicative of allergic disease as we know that wheeze may be induced by viral infection (59).

**Conclusion**

In summary, our data indicate an inverse association between cord serum 25(OH)D levels and the risk of early transient wheezing and atopic dermatitis in young children. In
contrast, we found no apparent association between cord serum 25(OH)D concentrations and other wheezing phenotypes, asthma and allergic rhinitis at 5 years of age.

If these associations are causal, interventions to increase vitamin D levels \textit{in utero} and in early life could reduce the risk of transient wheezing and atopic dermatitis in early childhood. Increased exposure to sunlight and increased intake of foods high in vitamin D (not necessarily supplementation) in both pregnant women and infants are potential public health interventions.

In light of recent findings on the role of vitamin D, and its effects on asthma and allergic diseases, studies of vitamin D may enhance the understanding, prevention and treatment of these increasingly common conditions in childhood. Further research is required to establish the optimal level (or range) of vitamin D that decreases both the risk for development and severity of these disorders, but also the timing and route of exposure to vitamin D.
References


### TABLE I. Comparison of basic characteristics of mother-newborn pairs with (n = 239) and without (n = 901) measurement of cord serum 25(OH)D

<table>
<thead>
<tr>
<th></th>
<th>Study sample with measurement (n = 239)</th>
<th>Sample without measurement (n = 901)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>City, %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poitiers</td>
<td>47.7</td>
<td>57.3</td>
<td></td>
</tr>
<tr>
<td>Nancy</td>
<td>52.3</td>
<td>42.7</td>
<td>0.008</td>
</tr>
<tr>
<td><em><em>Maternal age, Mean ± SD</em> (years)</em>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 25, %</td>
<td>9.2</td>
<td>11.6</td>
<td>0.6</td>
</tr>
<tr>
<td>25-34, %</td>
<td>69.5</td>
<td>71.1</td>
<td></td>
</tr>
<tr>
<td>&gt; 34, %</td>
<td>21.3</td>
<td>17.4</td>
<td>0.3</td>
</tr>
<tr>
<td><strong>BMI, Mean ± SD (kg/m²)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal, %</td>
<td>46.8</td>
<td>45.9</td>
<td></td>
</tr>
<tr>
<td>Overweight, %</td>
<td>36.7</td>
<td>37.1</td>
<td></td>
</tr>
<tr>
<td>Moderate obesity, %</td>
<td>11.4</td>
<td>11.6</td>
<td></td>
</tr>
<tr>
<td>Severe obesity, %</td>
<td>5.1</td>
<td>5.4</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>Maternal allergies, %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal</td>
<td>31.4</td>
<td>31.0</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>Paternal allergies, %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paternal</td>
<td>23.0</td>
<td>22.3</td>
<td>0.8</td>
</tr>
<tr>
<td><strong>Maternal educational level, %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary school or less</td>
<td>3.3</td>
<td>4.9</td>
<td></td>
</tr>
<tr>
<td>Secondary school</td>
<td>56.2</td>
<td>59.3</td>
<td></td>
</tr>
<tr>
<td>University degree or higher</td>
<td>40.5</td>
<td>35.9</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Paternal educational level, %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary school or less</td>
<td>8.2</td>
<td>7.2</td>
<td></td>
</tr>
<tr>
<td>Secondary school</td>
<td>64.3</td>
<td>65.0</td>
<td></td>
</tr>
<tr>
<td>University degree or higher</td>
<td>27.5</td>
<td>27.8</td>
<td>0.7</td>
</tr>
<tr>
<td><strong>Smoking during pregnancy (active, passive), %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Environmental tobacco smoke exposure of the child (0–3 years), %</td>
<td>31.9</td>
<td>31.8</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Environmental tobacco smoke exposure of the child (0–3 years), %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dampness in housing (0–3 years), %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Attending daycare (0–1 years), %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Household income (Euros), %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 2300</td>
<td>36.0</td>
<td>43.0</td>
<td>0.06</td>
</tr>
<tr>
<td>&gt; 2300</td>
<td>64.0</td>
<td>57.0</td>
<td></td>
</tr>
<tr>
<td><strong>Older siblings, %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>45.6</td>
<td>49.0</td>
<td></td>
</tr>
<tr>
<td>1-2</td>
<td>48.1</td>
<td>47.5</td>
<td></td>
</tr>
<tr>
<td>≥3</td>
<td>6.3</td>
<td>3.6</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Birth weight, Mean (kg) ± SD</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.4 ± 0.5</td>
<td>3.3 ± 0.5</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td><strong>Gestational age at birth, Mean (weeks) ± SD</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39.5 ± 1.5</td>
<td>39.2 ± 1.8</td>
<td>0.3</td>
<td></td>
</tr>
<tr>
<td><strong>Sex of the newborn, %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>41.8</td>
<td>48.0</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>58.2</td>
<td>52.1</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Season of birth, %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summer</td>
<td>23.4</td>
<td>26.9</td>
<td></td>
</tr>
<tr>
<td>Autumn</td>
<td>20.5</td>
<td>23.1</td>
<td></td>
</tr>
<tr>
<td>Winter</td>
<td>16.7</td>
<td>23.8</td>
<td></td>
</tr>
<tr>
<td>Spring</td>
<td>39.3</td>
<td>23.3</td>
<td>0.0008</td>
</tr>
<tr>
<td><strong>Exclusively breastfed for ≥ 4 months, %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.3</td>
<td>14.8</td>
<td>0.6</td>
<td></td>
</tr>
</tbody>
</table>

* SD = standard deviation
TABLE II. Association between cord blood 25(OH)D levels (per 5 ng/mL increase) and risk of wheeze and atopic dermatitis outcomes, and asthma and allergic rhinitis (n = 239)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Unadjusted</th>
<th>Adjusted †</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI) *</td>
<td></td>
</tr>
<tr>
<td><strong>Wheeze</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early transient</td>
<td>0.77 (0.69–0.95), <em>P</em> = 0.01</td>
<td>0.67 (0.54–0.81), <em>P</em> = 0.0002</td>
</tr>
<tr>
<td>Late-onset</td>
<td>0.94 (0.77–1.16), <em>P</em> = 0.58</td>
<td>0.86 (0.67–1.11), <em>P</em> = 0.24</td>
</tr>
<tr>
<td>Persistent</td>
<td>1.10 (0.70–0.95), <em>P</em> = 0.50</td>
<td>1.15 (0.79–1.691), <em>P</em> = 0.46</td>
</tr>
<tr>
<td><strong>Atopic dermatitis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>By the age of 1</td>
<td>0.88 (0.76–1.00), <em>P</em> = 0.08</td>
<td>0.84 (0.71–1.00), <em>P</em> = 0.05</td>
</tr>
<tr>
<td>By the age of 2</td>
<td>0.86 (0.77–1.00), <em>P</em> = 0.05</td>
<td>0.82 (0.70–0.95), <em>P</em> = 0.02</td>
</tr>
<tr>
<td>By the age of 3</td>
<td>0.87 (0.76–1.00), <em>P</em> = 0.05</td>
<td>0.82 (0.68–0.97), <em>P</em> = 0.02</td>
</tr>
<tr>
<td>By the age of 5</td>
<td>0.82 (0.71–0.91), <em>P</em> = 0.003</td>
<td>0.75 (0.63–0.88), <em>P</em> = 0.0005</td>
</tr>
<tr>
<td>Early-onset</td>
<td>0.82 (0.70–0.95), <em>P</em> = 0.01</td>
<td>0.73 (0.62–0.90), <em>P</em> = 0.002</td>
</tr>
<tr>
<td>Late-onset</td>
<td>0.82 (0.68–0.98), <em>P</em> = 0.03</td>
<td>0.75 (0.60–0.94), <em>P</em> = 0.01</td>
</tr>
<tr>
<td><strong>Asthma at 5</strong></td>
<td>1.09 (0.87–1.38), <em>P</em> = 0.42</td>
<td>1.07 (0.78–1.45), <em>P</em> = 0.69</td>
</tr>
<tr>
<td><strong>Allergic rhinitis at 5</strong></td>
<td>1.06 (0.84–1.34), <em>P</em> = 0.62</td>
<td>0.99 (0.72–1.38), <em>P</em> = 0.98</td>
</tr>
</tbody>
</table>

*OR (95 % CI): odd ratio and 95% confidence interval. † Adjusted for city, mother’s age, maternal history of allergy, pre-pregnancy body mass index, any smoking during pregnancy, any passive smoke exposure during the first 3 years of life, number of siblings, household income, newborn’s sex and weight, season of birth, and exclusive breastfeeding for ≥ 4 months.‡P = P-value.
Figure legends

**FIG 1.** Distribution of vitamin D levels in cord blood (ng/mL). Vitamin D levels are indicated on the x-axis and percentages of newborns are indicated on the y-axis. IQR = interquartile range. To convert ng/mL 25-hydroxyvitamin D to nmol/L, multiply ng/mL by 2.496.

**FIG 2.** Adjusted associations between cord serum 25(OH)D levels and predicted probabilities of atopic dermatitis by age of 5 years.